[go: up one dir, main page]

BE898946A - Nouveaux antagonistes des recepteurs de l'adenosine - Google Patents

Nouveaux antagonistes des recepteurs de l'adenosine

Info

Publication number
BE898946A
BE898946A BE0/212418A BE212418A BE898946A BE 898946 A BE898946 A BE 898946A BE 0/212418 A BE0/212418 A BE 0/212418A BE 212418 A BE212418 A BE 212418A BE 898946 A BE898946 A BE 898946A
Authority
BE
Belgium
Prior art keywords
receptor antagonists
adenosine receptor
xanthine
dipropyl
novel adenosine
Prior art date
Application number
BE0/212418A
Other languages
English (en)
Inventor
S H Snyder
J W Daly
R F Bruns
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of BE898946A publication Critical patent/BE898946A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

De nouvelles 8-phénylxanthines, comme la 1,3-dipropyl-8-(2-amino-4-chlorophényl)xanthine, la 1,3-dipropyl-8-(2,4-diaminophényl)xanthine, la 8-(2-amino-4-chlorophényl)théophylline et la 1,3-dipropyl-8-phényl-xanthine, sont de puissants antagonistes des récepteurs de l'adénosine. La très haute activité de ces composés permet de les utiliser en concentrations plus faibles que les xanthines déjà connues et ainsi d'atténuer les effets secondaires observés.
BE0/212418A 1983-02-18 1984-02-17 Nouveaux antagonistes des recepteurs de l'adenosine BE898946A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/467,894 US4593095A (en) 1983-02-18 1983-02-18 Xanthine derivatives

Publications (1)

Publication Number Publication Date
BE898946A true BE898946A (fr) 1984-06-18

Family

ID=23857582

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/212418A BE898946A (fr) 1983-02-18 1984-02-17 Nouveaux antagonistes des recepteurs de l'adenosine

Country Status (10)

Country Link
US (1) US4593095A (fr)
JP (1) JPS59205377A (fr)
BE (1) BE898946A (fr)
CA (1) CA1234804A (fr)
DE (1) DE3406275A1 (fr)
FR (1) FR2541281B1 (fr)
GB (2) GB8403574D0 (fr)
IT (1) IT1196031B (fr)
NL (1) NL8400514A (fr)
SE (1) SE456680B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755517A (en) * 1986-07-31 1988-07-05 Warner-Lambert Company Derivatives of xanthine, pharmaceutical compositions and methods of use therefor

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769377A (en) * 1983-02-18 1988-09-06 The Johns Hopkins University Adenosine receptor antagonists
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
US5017577A (en) * 1986-04-25 1991-05-21 Burroughs Wellcome Co. Methods for treating viral infection
US4772607A (en) * 1986-05-20 1988-09-20 Warner-Lambert Company Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor
JPS63154687A (ja) * 1986-11-13 1988-06-27 マリオン・ラボラトリーズ・インコーポレーテッド ８ーアリールキサンチン
US4783530A (en) * 1986-11-13 1988-11-08 Marion Laboratories, Inc. 8-arylxanthines
US5015647A (en) * 1987-04-24 1991-05-14 Burroughs Wellcome Co. Method for treating viral infections
US5032593A (en) * 1988-07-01 1991-07-16 Marion Merrell Dow Inc. Method of treating bronchoconstriction with 1,3-unsymmetrical straight chain alkyl-substituted 8-phenylxanthines
US5298508A (en) * 1988-07-19 1994-03-29 The United States Of America As Represented By The Department Of Health And Human Services Irreversible inhibitors of adenosine receptors
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
NZ240644A (en) * 1990-11-21 1994-08-26 Smithkline Beecham Corp Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
TW252044B (fr) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
US5877179A (en) * 1992-09-29 1999-03-02 The United States Of America As Represented By The Department Of Health And Human Services Xanthines for identifying CFTR--binding compounds useful for activating chloride conductance in animal cells
AU6781194A (en) * 1993-05-03 1994-11-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
US5504090A (en) * 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
GB9415529D0 (en) 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US6930101B1 (en) * 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
ES2166270B1 (es) 1999-07-27 2003-04-01 Almirall Prodesfarma Sa Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
US6815446B1 (en) 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
AU7962000A (en) * 1999-10-29 2001-05-14 Kyowa Hakko Kogyo Co. Ltd. Us0027324for eating disorders
CA2671940A1 (fr) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Procede permettant d'identifier des agonistes partiels du recepteur a2a
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
HU229504B1 (hu) 2001-11-09 2014-01-28 Gilead Sciences A2B-adenozinreceptor-antagonisták
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
KR20040080939A (ko) * 2002-02-01 2004-09-20 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 8-헤테로아릴 크산틴 아데노신 에이투비 수용체 길항제
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
KR20050026546A (ko) * 2002-07-29 2005-03-15 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ2ａ 수용체 작용제를 이용한 심근 관류 조영
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
ES2387653T3 (es) * 2004-09-01 2012-09-27 Gilead Sciences, Inc. Procedimiento de cicatrización de heridas utilizando antagonistas del receptor de adenosina A2B
WO2006044856A2 (fr) 2004-10-20 2006-04-27 Cv Therapeuitics, Inc. Utilisation d'agonistes du recepteur de l'adenosine a2a
KR101494125B1 (ko) * 2006-02-03 2015-02-16 길리애드 사이언시즈, 인코포레이티드 Ａ2ａ-아데노신 수용체 효능제 및 이의 다형체의 제조 방법
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
CA2662278C (fr) * 2006-09-01 2011-11-22 Cv Therapeutics, Inc. Methodes et compositions permettant d'augmenter la tolerabilite de patients pendant des methodes d'imagerie myocardique
JP2011502101A (ja) * 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド 肺疾患の病歴を有する患者における心筋画像化法
US20080267861A1 (en) * 2007-01-03 2008-10-30 Cv Therapeutics, Inc. Myocardial Perfusion Imaging
MX2011003168A (es) * 2008-09-29 2011-05-19 Gilead Sciences Inc Combinaciones de un agente de control de cantidad y un antagonista del receptor a-2-alfa para utilizarse en metodos de tomografia computarizada de detectores multiples.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2840559A (en) * 1954-06-22 1958-06-24 Krantz Jr Nuclearly substituted 8-theophyllines and method of making the same
DE1091570B (de) * 1958-10-23 1960-10-27 Albert Ag Chem Werke Verfahren zur Herstellung von in 8-Stellung substituierten 1, 3-Dialkylxanthinen
GB982079A (en) * 1962-05-01 1965-02-03 Dresden Arzneimittel Process for the production of xanthine derivatives
BE636699A (fr) * 1962-08-31
EP0011399A1 (fr) * 1978-11-11 1980-05-28 FISONS plc Théophyllines-N-substituées, procédés pour leur préparation et compositions pharmaceutiques les contenant
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755517A (en) * 1986-07-31 1988-07-05 Warner-Lambert Company Derivatives of xanthine, pharmaceutical compositions and methods of use therefor

Also Published As

Publication number Publication date
SE8400788D0 (sv) 1984-02-14
DE3406275A1 (de) 1984-09-27
GB8404243D0 (en) 1984-03-21
IT8419675A1 (it) 1985-08-17
JPS59205377A (ja) 1984-11-20
SE456680B (sv) 1988-10-24
IT8419675A0 (it) 1984-02-17
SE8400788L (sv) 1984-08-19
CA1234804A (fr) 1988-04-05
IT1196031B (it) 1988-11-10
GB2135311A (en) 1984-08-30
GB8403574D0 (en) 1984-03-14
NL8400514A (nl) 1984-09-17
FR2541281B1 (fr) 1988-01-29
GB2135311B (en) 1986-11-05
FR2541281A1 (fr) 1984-08-24
US4593095A (en) 1986-06-03

Similar Documents

Publication Publication Date Title
BE898946A (fr) Nouveaux antagonistes des recepteurs de l'adenosine
IT1206078B (it) Procedimento per la produzione di acido 3-indolpiruvico e suoi derivati loro uso farmaceutico
DE69422191D1 (de) A1 adenosin rezeptor agonisten und antagonisten
BG101806A (bg) Индолови производни като антагонисти на 5-нт рецептори
ES2021143B3 (es) Proceso mejorado para preparar composiciones oleaginosas estables.
ES2038613T3 (es) Procedimiento para preparar derivados de 4,5,6,7-tetrahidro-1h-imidazo(4,5-c)piridina y analogos de los mismos que tienen actividad antihipertensiva.
BR8707609A (pt) Composto aditivo para fluidos funcionais,processo para preparar um composto aditivo,composto aditivo,complexo aditivo,aditivo concentrado,composicao lubrificante,composicao aditiva e composicao combustivel
FI931370A0 (fi) Kvaeve innehaollande analoger av icke-aromatiska heterocykliska foereningar med en fusionerad ring
NO912606L (no) Fremgangsmaate for fremstilling av 9-purinylfosfonsyrederivater.
ZA839693B (en) Substituted 4-aminomethylene-chromans and-chromens,processes for their preparation and their use in medicaments
DK186087D0 (da) Anvendelse af pseudomonsyre til behandling af fungale infektioner
DK1019426T3 (da) Hidtil ukendte A1-adenosinreceptoragonister og -antagonister
ATE16489T1 (de) Aroylimidazolone.
DK155321C (da) Analogifremgangsmaade til fremstilling af 3,4,5-trihydroxypiperidinderivater
ES2078519T3 (es) Acidos hidroxamicos ciclicos y su uso.
BG99638A (en) Derivatives of xanthine as diuretic form
ATE11545T1 (de) Gesaettigte aminocyclitderivate, ihre herstellung und sie enthaltende arzneimittel.
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
NL7614212A (nl) Modacrylvezels, die stabiel zijn wat betreft hun glans en werkwijze voor het vervaardigen ervan.
ATE3033T1 (de) Derivate des 2-hydroxymethyl-3,4,5-trihydroxypiperidins, ihre herstellung und sie enthaltende arzneimittel.
ES549982A0 (es) Procedimiento para preparar 6-sustituido-5-feniltetrazol (1,5-a)-(1,2,4)triazol-(1,5-c)pirimidinas
BR8103208A (pt) Compostos quimicos que sao novos derivados de quinoxalina 1,4-dioxido,processo para sua prepacao,composicoes que os contem,concentrado para forragem,processo para preparacao deste concentrado e processo para aumentar o ganho de peso no uso de racoes
SU1469946A1 (ru) Состав для обработки призабойной зоны пласта
ES524453A0 (es) Un procedimiento para la obtencion de un tautomero de pirazoloquinolinas
ES2056873T3 (es) Derivados de 1-acil-2,3-dihidro-4-(1h)-quinolinona-4-oxima, procedimiento para producirlos y uso de los mismos.

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: THE JOHNS HOPKINS UNIVERSITY

Effective date: 19940228